What is the treatment of Livedoid vasculopathy?

Livedoid vasculopathy (EF50) is treated with a structured first-line protocol centred on rapid pain relief. The approach involves anticoagulant therapy initiated at a therapeutic level and adjusted as the clinical picture evolves.

Treatment approach

First-line management involves low-molecular-weight heparin, started at a full therapeutic level. Once findings are stable, the regimen transitions to a reduced maintenance level.

Complete dosing schedule, adjustment criteria, and monitoring details are available in the full structured protocol.

Clinical goal

Pain relief is the primary short-term endpoint. A therapeutic response can be expected and assessed within the first few days after starting treatment.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/ddg.14520

Treatment with low-molecular-weight heparin should be initiated at the full therapeutic dose (for example enoxaparin 1 mg/kg BW subcutaneously twice a day in the morning and evening (off label))
Once findings are stable, dosage should be reduced to a semi-therapeutic level (for example enoxaparin 1 mg/kg BW subcutaneously once a day (off label))
The time lag between initiation of treatment or increasing the dose and the resulting pain relief is 2–4 days, so the therapeutic response can be assessed rapidly.

View source ↗